Lifitegrast
Product Specifications
UNSPSC Description
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease[1].
Target Antigen
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Lifitegrast.html
Purity
99.29
Solubility
DMSO : ≥ 29 mg/mL
Smiles
O=C(O)[C@H](CC1=CC=CC(S(=O)(C)=O)=C1)NC(C2=C(Cl)C3=C(CN(C(C4=CC=C5C=COC5=C4)=O)CC3)C=C2Cl)=O
Molecular Weight
615.48
References & Citations
[1]Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15.|[2]Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402.|[3]Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-19344/Lifitegrast-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-19344/Lifitegrast-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
1025967-78-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6158412-01 0.1 mL
IRAK4 (Interleukin-1 Receptor-associated Kinase 4, IRAK-4, Renal Carcinoma Antigen NY-REN-64) (PE)
Ask
View Details MBS6158412-02 5x 0.1 mL
IRAK4 (Interleukin-1 Receptor-associated Kinase 4, IRAK-4, Renal Carcinoma Antigen NY-REN-64) (PE)
Ask
View Details 
